New Vaccine Platform Shows Promise in Generating HIV-Neutralizing Antibodies

Researchers at MIT and the Scripps Research Institute have developed a novel vaccine platform utilizing a DNA-based virus-like particle (VLP) that significantly enhances the production of rare precursor B cells capable of evolving into broadly neutralizing antibodies against HIV. This breakthrough addresses a longstanding challenge in vaccine development – inducing immune responses against rapidly mutating viruses like HIV and influenza.

The Challenge of HIV Vaccine Development

A key goal in immunotherapy and vaccine research is to elicit broadly neutralizing antibodies (bnAbs), which can neutralize multiple strains of a virus. HIV’s rapid mutation rate and ability to evade the immune system have made developing an effective vaccine exceptionally tricky. Inducing bnAbs requires stimulating the immune system to generate specific B cells, but these precursor cells are exceptionally rare.

DNA-Based Vaccine Platform Outperforms Traditional Approaches

The new approach centers on constructing a virus-like particle using a DNA scaffold, rather than a protein scaffold. This DNA VLP displays multiple copies of an engineered HIV immunogen, eOD-GT8, originally developed at Scripps Research. In preclinical studies using a humanized mouse model, the DNA-based particle generated substantially more of the desired precursor B cells compared to a protein-based VLP currently in clinical trials. Specifically, the DNA scaffold induced approximately eight times more on-target B cells.

“We were all surprised that this already outstanding virus-like particle from Scripps was significantly outperformed by the DNA-based virus-like particle,” said Dr. Mark Bathe, professor of biological engineering at MIT MIT News.

Key Advantages of the DNA Scaffold

• Reduced Off-Target Immune Responses: The DNA scaffold itself did not provoke a significant immune response, preventing the immune system from diverting resources away from the intended viral target.
• Enhanced Retention in Lymph Nodes: The DNA particles demonstrated improved retention within B cell follicles in lymph nodes, promoting more effective interaction with helper T cells crucial for B cell maturation.
• Potential for Complex Boosting Strategies: The immunological silence of the DNA platform allows for sequential delivery of multiple antigens, a strategy considered essential for tackling complex targets like HIV.

“This study showed convincingly that reducing off-target responses through use of a DNA virus-like particle can improve desired on-target responses,” said Dr. William Schief of the Scripps Research Institute’s department of immunology and microbiology MIT News.

Implications Beyond HIV

Researchers suggest the DNA-based VLP technology could have broader applications beyond HIV. It may improve vaccine responses against other pandemic threats, such as influenza, and potentially support the development of immunotherapies for neurodegenerative disorders or addiction by inducing highly focused antibody responses.

Recent Advances in HIV Vaccine Research

This development builds upon previous research. In June 2025, Scripps Research scientists reported a two-part vaccine strategy using two adjuvants to generate a stronger and longer-lasting immune boost against HIV Scripps Research. Also in June 2025, MIT and Scripps researchers demonstrated the ability to generate a strong immune response to HIV with a single vaccine dose by combining the vaccine candidate with two adjuvants MIT News.

The function is part of a larger international effort to design vaccines that selectively expand specific lineages of B cells, crucial for generating effective broadly neutralizing antibodies against HIV.